Ultrasound helps prevent stroke in children with sickle cell disease
A new study from researchers at the University of Michigan Comprehensive Cancer Center found that a tool commonly used by doctors to estimate the risk of a woman’s breast cancer returning after surgery is not very effective at explaining risk to patients. As a result, women with breast cancer may not find these tools helpful
Full Post: Confusing risk information may lead breast cancer patients to make poor treatment choices
Screening with an ultrasound machine has proved highly successful in preventing stroke among children with sickle cell disease, by identifying children who are then preventively treated with blood transfusions.
Over an eight-year period at The Children’s Hospital of Philadelphia, researchers found that the technique, transcranial Doppler ultrasonography (TCD), along with regular transfusions for children found to be at high risk, reduced stroke to one-tenth of the incidence found before TCD was introduced.
“We studied the impact of using TCD starting in 1998, when the technique became routine at our hospital and many other centers,” said Janet L. Kwiatkowski, M.D., a pediatric hematologist at The Children’s Hospital of Philadelphia. Kwiatkowski presented her group’s results today at a press conference during the 50th annual meeting of the American Society of Hematology.
Childhood stroke has long been known to be a devastating complication of sickle cell disease, an inherited condition in which abnormal hemoglobin deforms red blood cells into sickle-shaped bodies that do not pass smoothly through blood vessels.
TCD is a noninvasive tool that uses ultrasound waves to measure the speed of blood flow in large vessels in the brain. An abnormally high speed is a marker of a narrowed vessel, and a sign of high risk for stroke.
After the multicenter Stroke Prevention Trial in Sickle Cell Anemia showed in 1998 the utility of TCD in detecting abnormal blood speeds and the benefit of transfusions in reducing stroke risk, the Sickle Cell Program at Children’s Hospital began to routinely use TCD in screening sickle cell patients. “When we see an abnormal TCD result, we treat the child with preventive blood transfusions, given regularly every three to four weeks,” said Kwiatkowski.
The current study compared the rate of stroke in children with sickle cell disease in the eight years before Children’s Hospital began TCD screening with the eight years from 1998 to 2006. The researchers followed 475 children in the pre-TCD group and 530 children in the post-TCD group.
In reviewing patient records, the researchers measured overt strokes, other neurological events and indeterminate events-those that could not be classified based on available information. In the pre-TCD group, there were 21 patients with overt stroke, three with other neurological events and two with indeterminate events. In contrast, the post-TCD group had two patients with overt stroke, six with other neurological events and one with an indeterminate event.
Overall, the incidence of overt stroke in the pre-TCD group was significantly higher compared to the post-TCD group-an incidence of 0.67 per 100 patient years compared to 0.06 per 100 patient years. “The study confirmed that a program of TCD screening combined with regular transfusion therapy for children found to be at high risk of stroke is effective in preventing strokes,” added Kwiatkowski.
A study assessing the quality of care for patients with sickle cell disease in a variety of hospital settings was presented Saturday, December 6 during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA. Two other studies on screening methods that help determine stroke risk in children with sickle cell
Full Post: Studies examine quality of care for hospitalized sickle cell disease patients
A unique approach to bone marrow transplantation pioneered in part by a Children’s Hospital of Pittsburgh of UPMC physician has proven to be the only safe and effective cure for sickle cell disease, according to a new study. Lakshmanan Krishnamurti, MD, a pediatric hematologist/oncologist at Children’s Hospital, helped pioneer a form of bone marrow transplantation
Full Post: New approach to bone marrow transplantation found to be a safe and effective cure for sickle cell disease
Researchers have identified a gene that directly affects the production of a form of hemoglobin that is instrumental in modifying the severity of the inherited blood disorders sickle cell disease and thalassemia. The discovery could lead to breakthrough therapies for sickle cell disease and thalassemia, which could potentially eliminate the devastating and life-threatening complications of
Full Post: Breakthrough in sickle cell disease and thalassemia research
A new study finds that youth populations with sickle cell disease (SCD) are receiving inadequate healthcare, and thus may fail to benefit from scientific advances. The study, published in Pediatric Blood & Cancer, finds that the patients, mostly African Americans, often lack insurance or access to specialized sickle cell centers for treatment. SCD, a blood
Full Post: Children with sickle cell disease have inadequate healthcare
Sickle cell anaemia is a genetic disease characterised by the sickling of red blood cells in patients suffering from hypoxia (around 100,000 cases in Europe and North America). The red blood cells then adopt a sickle shape, obstruct the blood vessels and cause repeated and very painful crises. Current treatment involves frequent and substantial exchange
Full Post: New advance in the treatment of sickle cell anaemia